妇科肿瘤与肿瘤内科专科诊疗对妇科癌症生存、医疗利用及费用的关联
该研究基于SEER-Medicare数据库纳入2000至2015年新诊断的III-IV期子宫、卵巢和宫颈癌化疗患者共7930例,比较妇科肿瘤(GYO)与肿瘤内科(MEDONC)诊疗与总生存、急诊利用、住院及费用的关联。卵巢癌患者接受GYO诊疗与总生存改善相关(中位OS 3.3年 vs 2.9年;HR 0.85,95%CI 0.80, 0.91,p<.0001),且每月平均费用相似;子宫癌患者GYO诊疗总生存相似但费用降低、急诊利用减少;宫颈癌患者总生存和费用均相似。
要点
- 卵巢癌患者接受妇科肿瘤诊疗与总生存改善相关(HR 0.85,95%CI 0.80, 0.91,p<.0001)。
- 子宫癌患者接受妇科肿瘤诊疗总生存相似,但费用降低且急诊利用减少。
- 卵巢癌和宫颈癌患者接受妇科肿瘤诊疗住院风险更高(RR 1.23和1.26)。
核心结论
- 晚期卵巢癌患者接受妇科肿瘤专科诊疗与总生存改善及费用相当相关。
- 子宫癌和宫颈癌患者接受妇科肿瘤诊疗的总生存分别相似,费用分别降低或相当。
研究设计与样本
- 基于SEER-Medicare数据库的回顾性队列研究,纳入2000至2015年新诊断的III-IV期子宫、卵巢和宫颈癌化疗患者共7930例(卵巢癌4360例、子宫癌2934例、宫颈癌643例)。
- 采用未校正及逆治疗概率加权倾向评分的多变量Cox模型、Poisson回归和对数转换数据的广义模型评估结局。
主要发现
- 37%的患者由妇科肿瘤专科诊疗,63%由肿瘤内科诊疗。
- 卵巢癌患者中,妇科肿瘤诊疗与总生存改善相关(中位OS 3.3年 vs 2.9年;HR 0.85,95%CI 0.80, 0.91,p<.0001),每月平均费用相似($4015 vs $4316,均值比0.97,95%CI 0.93, 1.02,p=.19)。
- 子宫癌患者中,妇科肿瘤诊疗与总生存相似相关,但费用降低($3573 vs $4081,均值比0.87,95%CI 0.81, 0.93,p<.0001),急诊利用减少(RR 0.76,95%CI 0.69, 0.85,p<.0001)。
- 宫颈癌患者中,妇科肿瘤诊疗与总生存相似和费用相似相关。
- 校正分析中,卵巢癌(RR 1.23,95%CI 1.11, 1.37,p=.0001)和宫颈癌(RR 1.26,95%CI 1.05, 1.51,p=.015)患者接受妇科肿瘤诊疗的住院风险更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We examined the association of gynecologic oncology (GYO) versus medical oncology (MEDONC) based care with survival, health care utilization and spending outcomes in women undergoing chemotherapy for advanced gynecologic cancers. METHODS: Women with newly diagnosed stage III-IV uterine, ovarian, and cervical cancers from 2000 to 2015 were identified in SEER-Medicare. We assessed the association of provider specialty with overall survival, emergency department utilization, admissions, and spending. Outcomes were assessed using unadjusted and Inverse Treatment Probability Weighted propensity-score applied, multi-variable cox modeling, Poisson regression, and generalized models of log-transformed data. RESULTS: We identified 7930 gynecologic cancer patients (4360 ovarian, 2934 uterine, 643 cervix). 37% were treated by GYO and 63% by MEDONC. For ovarian patients, GYO care was associated with improved OS (median OS 3.3 v. 2.9 years; HR 0.85, 95%CI 0.80, 0.91, p < .0001) and similar mean spending per month ($4015 v. $4316, mean ratio 0.97 (95% CI 0.93, 1.02), p = .19), compared to MEDONC in adjusted analyses. For uterine patients, GYO care was associated with similar OS, but decreased spending ($3573 v. $4081, mean ratio 0.87 (95% CI.81, 0.93), p < .0001), and decreased ED utilization (RR 0.76, 95% CI 0.69, 0.85, p < .0001). For cervical patients, GYO care was associated with similar OS, and similar spending. Admissions were more likely in ovarian (RR 1.23, 95%CI 1.11, 1.37, p = .0001) and cervical patients (RR 1.26, 95% CI 1.05, 1.51, p = .015) treated by GYO, in adjusted analyses. CONCLUSIONS: GYO based care was associated with improved OS and equal spending for patients with advanced stage ovarian cancer. Uterine and cervix patients had similar OS, and less or equal spending respectively, when treated by GYO compared to MEDONC.
引用
- Ko EM, Bekelman JE, Hicks-Courant K, et al. Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers. Gynecol Oncol. 2021. PMID: 34949437. doi:10.1016/j.ygyno.2021.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。